Sharon X. Wen

Array ( [id] => 10381967 [patent_doc_number] => 20150266974 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-09-24 [patent_title] => 'ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING' [patent_app_type] => utility [patent_app_number] => 14/677983 [patent_app_country] => US [patent_app_date] => 2015-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 32719 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14677983 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10103874 [patent_doc_number] => 09139648 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2015-09-22 [patent_title] => 'Precision medicine by targeting human NAV1.9 variants for treatment of pain' [patent_app_type] => utility [patent_app_number] => 14/665579 [patent_app_country] => US [patent_app_date] => 2015-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 4 [patent_no_of_words] => 229407 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 181 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14665579 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10115792 [patent_doc_number] => 09150660 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2015-10-06 [patent_title] => 'Precision Medicine by targeting human NAV1.8 variants for treatment of pain' [patent_app_type] => utility [patent_app_number] => 14/665532 [patent_app_country] => US [patent_app_date] => 2015-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 4 [patent_no_of_words] => 229367 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 197 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14665532 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10070693 [patent_doc_number] => 09109034 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2015-08-18 [patent_title] => 'Precision medicine by targeting PD-L1 variants for treatment of cancer' [patent_app_type] => utility [patent_app_number] => 14/659910 [patent_app_country] => US [patent_app_date] => 2015-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 4 [patent_no_of_words] => 183158 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 186 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14659910 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10399464 [patent_doc_number] => 20150284473 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-08 [patent_title] => 'METHODS FOR REDUCING CARDIOVASCULAR RISK' [patent_app_type] => utility [patent_app_number] => 14/657192 [patent_app_country] => US [patent_app_date] => 2015-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 21342 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14657192 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10346231 [patent_doc_number] => 20150231236 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-20 [patent_title] => 'METHODS FOR TREATING PATIENTS WITH HYPERCHOLESTEROLEMIA THAT IS NOT ADEQUATELY CONTROLLED BY MODERATE-DOSE STATIN THERAPY' [patent_app_type] => utility [patent_app_number] => 14/621000 [patent_app_country] => US [patent_app_date] => 2015-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 32833 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14621000 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10553935 [patent_doc_number] => 09278129 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-03-08 [patent_title] => 'Methods of treating rapidly progressive glomerulonephritis using chimeric and humanized anti-histone H4 antibodies' [patent_app_type] => utility [patent_app_number] => 14/620315 [patent_app_country] => US [patent_app_date] => 2015-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 36980 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14620315 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12254232 [patent_doc_number] => 09926368 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-03-27 [patent_title] => 'Method for treating muscle wasting syndrome using antagonist antibodies against GDF-8' [patent_app_type] => utility [patent_app_number] => 14/603231 [patent_app_country] => US [patent_app_date] => 2015-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 39 [patent_no_of_words] => 33298 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14603231 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17015257 [patent_doc_number] => 11084884 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-10 [patent_title] => Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema [patent_app_type] => utility [patent_app_number] => 15/113297 [patent_app_country] => US [patent_app_date] => 2015-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 19071 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15113297 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10225776 [patent_doc_number] => 20150110769 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-04-23 [patent_title] => 'METHOD FOR RETARDING UNHEALTHY MANIFESTATIONS BROUGHT BY AGEING OF HUMAN BEINGS' [patent_app_type] => utility [patent_app_number] => 14/579041 [patent_app_country] => US [patent_app_date] => 2014-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 3898 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14579041 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11305026 [patent_doc_number] => 09512411 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-12-06 [patent_title] => 'Nucleic acid encoding antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK' [patent_app_type] => utility [patent_app_number] => 14/571433 [patent_app_country] => US [patent_app_date] => 2014-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 13510 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14571433 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10267195 [patent_doc_number] => 20150152193 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-04 [patent_title] => 'AXL ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/563353 [patent_app_country] => US [patent_app_date] => 2014-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 28475 [patent_no_of_claims] => 49 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14563353 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10202831 [patent_doc_number] => 20150087819 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-26 [patent_title] => 'ANTIGEN BINDING PROTEINS TO PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (PCSK9)' [patent_app_type] => utility [patent_app_number] => 14/562546 [patent_app_country] => US [patent_app_date] => 2014-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 152 [patent_figures_cnt] => 152 [patent_no_of_words] => 73139 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14562546 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10265958 [patent_doc_number] => 20150150956 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-04 [patent_title] => 'EPITOPE COMPOSITION' [patent_app_type] => utility [patent_app_number] => 14/556930 [patent_app_country] => US [patent_app_date] => 2014-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 3581 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14556930 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10281681 [patent_doc_number] => 20150166677 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-18 [patent_title] => 'HUMAN TARGETS' [patent_app_type] => utility [patent_app_number] => 14/552816 [patent_app_country] => US [patent_app_date] => 2014-11-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 55792 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14552816 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16061433 [patent_doc_number] => 10689651 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-23 [patent_title] => Method of inhibiting macrophage activation using an inhibitor of PARP9 [patent_app_type] => utility [patent_app_number] => 15/036249 [patent_app_country] => US [patent_app_date] => 2014-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 56 [patent_figures_cnt] => 54 [patent_no_of_words] => 32089 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15036249 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10267194 [patent_doc_number] => 20150152191 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-04 [patent_title] => 'DOSING REGIMENS FOR USE WITH PCSK9 INHIBITORS' [patent_app_type] => utility [patent_app_number] => 14/539199 [patent_app_country] => US [patent_app_date] => 2014-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 28775 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14539199 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10026109 [patent_doc_number] => 09067998 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2015-06-30 [patent_title] => 'Targeting PD-1 variants for treatment of cancer' [patent_app_type] => utility [patent_app_number] => 14/537403 [patent_app_country] => US [patent_app_date] => 2014-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 4 [patent_no_of_words] => 200307 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 182 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14537403 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10019634 [patent_doc_number] => 09062105 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2015-06-23 [patent_title] => 'Precision Medicine by targeting VEGF-A variants for treatment of retinopathy' [patent_app_type] => utility [patent_app_number] => 14/536129 [patent_app_country] => US [patent_app_date] => 2014-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 4 [patent_no_of_words] => 183012 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14536129 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10001466 [patent_doc_number] => 09045545 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2015-06-02 [patent_title] => 'Precision medicine by targeting PD-L1 variants for treatment of cancer' [patent_app_type] => utility [patent_app_number] => 14/536049 [patent_app_country] => US [patent_app_date] => 2014-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 4 [patent_no_of_words] => 183004 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14536049 [rel_patent_id] =>[rel_patent_doc_number] =>)